Amphastar Pharmaceuticals has reported boosted net revenue in its first quarter of 2024, which was driven by sales and payments linked to the hypoglycemia treatment Baqsimi (glucagon) that was acquired by the company last year.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?